Atorvastatin and losartan may upregulate renalase activity in hypertension but not coronary artery diseases: The role of gene polymorphism

Abstract

The aim is to explore the treatment effect of coronary artery disease (CAD) and hypertension on plasma levels of renalase activity and also the possible association of renalase rs10887800 gene polymorphism with CAD and hypertension. A total of 286 patients who received coronary angiography were included in the study. Subjects were divided into four groups including (1) hypertensive with no CAD (H‐Tens, n\u2009=\u200960); (2) CAD with hypertension (CAD\u2009+\u2009H‐Tens, n\u2009=\u200971); (3) CAD with no hypertension (CAD, n\u2009=\u200961); and (4) nonhypertensive with no CAD as a control group (Con, n\u2009=\u200969). The plasma renalase activity was measured using the Amplex Red Monoamine Oxidase Assay Kit. Renalase rs10887800 single‐nucleotide polymorphisms (SNPs) were genotyped by polymerase chain reaction‐restriction fragment length polymorphism (PCR‐RFLP) method. Atorvastatin (P\u2009=\u20090.005), losartan (P\u2009<\u20090.001), and captopril (P\u2009=\u20090.001) were administered significantly more in case groups compared with the Con group. Significant higher and lower levels of renalase activity were observed in H‐Tens and CAD patients compared with control subjects (P\u2009<\u20090.001 for both comparisons). Furthermore, no significant differences were obtained in the risk or protective effects of renalase rs10887800 SNP against hypertension and/or CAD in both recessive and dominant genetic models (P\u2009>\u20090.05). According to the findings of the present study, atorvastatin and losartan therapy assumes considerable significance in alleviating hypertension, but not CAD, by increasing the renalase activity. Furthermore, it was found that renalase rs10887800 is less likely a predisposing factor for susceptibility to hypertension and/or CAD in an Iranian southeast population.